The Best Supportive Care in Stage III Non-Small-Cell Lung Cancer

Curr Oncol. 2023 Dec 29;31(1):183-202. doi: 10.3390/curroncol31010012.

Abstract

Lung cancer is a major cause of cancer deaths worldwide. Non-small-cell lung cancer (NSCLC) represents most lung cancer cases, and approximately one-third of patients present with stage III disease at diagnosis. As multiple treatment plans can be adopted for these patients depending on tumor size and nodal staging, stage III NSCLC management is challenging. Over the past decades, multidisciplinary teams (MDTs) have been implemented in healthcare services to coordinate actions among the different health care professionals involved in cancer care. The aim of this review was to discuss real-world evidence of the impact of MDTs on stage III NSCLC management, survival, and quality of life. Here, we performed a literature review to investigate the role of nutrition and navigational nursing in NSCLC care and the influence of MDTs in the choice of treatment plans, including immunotherapy consolidation, and in the management of chemotherapy and radiotherapy-related adverse events. We also performed a mapping review to identify gaps in the implementation of cancer care MDTs in healthcare services around the world.

Keywords: adverse events; chemoradiotherapy; immune checkpoint inhibitors; mapping review; multidisciplinary teams; non-small-cell lung cancer.

Publication types

  • Review

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / therapy
  • Health Personnel
  • Humans
  • Immunotherapy
  • Lung Neoplasms* / therapy
  • Quality of Life

Grants and funding

This paper was supported by an unconditional grant (D133HR00004) from AstraZeneca for editorial assistance provided by Corebox (São Paulo, Brazil). The sponsor has no role in the manuscript drafting or in the decision to submit it.